Journal home
Advance online publication
Current issue
Archive
Press releases
Supplements
Focuses
Guide to authors
Online submissionOnline submission
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
Reprints and permissions
About this site
For librarians
 
NPG Resources
Nature
Nature Reviews
Nature Immunology
Nature Cell Biology
Nature Genetics
news@nature.com
Nature Conferences
Dissect Medicine
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Article
Nature Medicine  2, 561 - 566 (1996)
doi:10.1038/nm0596-561

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr−Abl positive cells

Brian J. Druker1, 3, Shu Tamura1, Elisabeth Buchdunger2, Sayuri Ohno1, Gerald M. Segal1, Shane Fanning1, Jürg Zimmermann2 & Nicholas B. Lydon2

  1Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA

  2Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland

  3Correspondence should be addressed to B.J.D.

The bcr−abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr−Abl fusion protein. Cellular proliferation and tumor formation by Bcr−Abl−expressing cells were specifically inhibited by this compound. In colony−forming assays of peripheral blood or bone marrow from patients with CML, there was a 92−98% decrease in the number of bcr−abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr−abl−positive leukemias.

REFERENCES
  1. Kantarjian, H.M., Deisseroth, A.B., Kurzrock, R., Estrov, Z., & Talpaz, M., Chronic myelogenous leukemia: A concise update. Blood 82, 691−703 (1993). | PubMed  | ISI | ChemPort |
  2. Allan, N.C., Shepard, P.C.A. & Richards, R.M. Interferon alpha prolongs survival for patients with CML in chronic phase: Preliminary results of the UK MRC randomized multicenter trial. Blood 84, 382a (1994).
  3. The Italian Cooperaticellve Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med. 330, 820−825 (1994). | ISI |
  4. Ozer, H., et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood. 82, 2975−2984 (1993). | PubMed  | ISI | ChemPort |
  5. O'Brien, S.G. & Goldman, J.M. Autografting in chronic myeloid leukaemia. Blood Rev. 8, 63−69 (1994). | PubMed  | ChemPort |
  6. McGlave, P.B., et al. Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups. Lancet 343, 1486−1488 (1994). | Article | PubMed  | ISI | ChemPort |
  7. O'Brien, S.G. & Goldman, J.M. Current approaches to hematopoietic stem-Cell purging in chronic myeloid leukemia. J. Clin. Oncol. 13, 541−546 (1995). | PubMed  | ChemPort |
  8. Nowell, P.C. & Hungerford, D.A. A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497−1501 (1960). | ISI |
  9. Rowley, J.D. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine, fluorescence and Giemsa staining. Nature. 243, 290−293 (1973). | PubMed  | ISI | ChemPort |
  10. Heisterkamp, N., et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukemia. Nature. 306, 239−242 (1983). | PubMed  | ISI | ChemPort |
  11. Bartram, C.R. et al. Translocation of c-abl correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature. 306, 277−280 (1983). | PubMed  | ISI | ChemPort |
  12. Shtivelman, E., Lifshitz, B., Gale, R.P. & Canaani, E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 315, 550−554 (1985). | PubMed  | ISI | ChemPort |
  13. Clark, S.S., et al. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science. 239, 775−777 (1988). | PubMed  | ISI | ChemPort |
  14. Scott, M.L., Van Etten, R., Daley, G.Q. & Baltimore, D. v-abl causes hematopoietic disease distinct from that caused by bcr-abl. Proc. Natl. Acad. Sci. USA. 88, 6506−6510 (1991). | PubMed  | ChemPort |
  15. Kelliher, M.A., McLaughlin, J., Witte, O.N. & Rosenberg, N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA. 87, 6649−6653 (1990). | PubMed  | ChemPort |
  16. Daley, G.Q., Van Etten, R.A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 247, 824−830 (1990). | PubMed  | ISI | ChemPort |
  17. Oda, T., Tamura, S., Matsuguchi, T., Griffin, J.D. & Druker, B.J. The SH2 domain of Abl is not required for factor independent growth induced by Bcr-Abl in a murine myeloid Cell line. Leukemia. 9, 295−301 (1995). | PubMed  | ISI | ChemPort |
  18. Lugo, T.G., Pendergast, A.M., Muller, A.J. & Witte, O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 247, 1079−1082 (1990). | PubMed  | ISI | ChemPort |
  19. Yaish, P., Gazit, A., Gilon, C. & Levitzki, A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242, 933−935 (1988). | PubMed  | ISI | ChemPort |
  20. Levitzki, A. & Gazit, A. Tyrosine kinase inhibition: An approach to drug development. Science. 267, 1782−1788 (1995). | PubMed  | ISI | ChemPort |
  21. Kaur, G., et al. Tyrphostin induced growth inhibition: Correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anti-Cancer Drugs. 5, 213−222 (1994). | PubMed  | ISI | ChemPort |
  22. Anafi, M., Gazit, A., Zehavi, A., Ben-Neriah, Y. & Levitzki, A. Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood. 82, 3524−3529 (1993). | PubMed  | ISI | ChemPort |
  23. Furet, P., et al. Modeling study of protein kinase inhibitors − binding mode of staurosporine and origin of the selectivity of CGP 52411. J Comput. Aided Mol. Des. 9, 465−472 (1995). | PubMed  | ISI | ChemPort |
  24. Laneuville, P., Heisterkamp, N. & Groffen, J. Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid Cell line. Oncogene 6, 275−282 (1991). | PubMed  | ISI | ChemPort |
  25. Matulonis, U., Salgia, R., Okuda, K., Druker, B. & Griffin, J.D. IL-3 and p210BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid Cell line. Exp. Hematol. 21, 1460−1466 (1993). | PubMed  | ISI | ChemPort |
  26. Daley, G.Q. & Baltimore, D. Transformation of an interleukin 3-dependent hematopoietic Cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. USA. 85, 9312−9316 (1988). | PubMed  | ChemPort |
  27. Honma, Y., Okabe, K.J., Hozumi, M., Uehara, Y. & Mizuno, S. Induction of ery-throid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res. 49, 331−4 (1989). | PubMed  | ISI | ChemPort |
  28. Schwartzberg, P.L., et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T Cell populations. Cell. 65, 1165−1175 (1991). | Article | PubMed  | ISI | ChemPort |
  29. Sawyers, C.L., McLaughlin, J., Goga, A., Havlik, M. & Witte, O. The nuclear tyrosine kinase c-Abl negatively regulates Cell growth. Cell. 77, 121−131 (1994). | Article | PubMed  | ISI | ChemPort |
  30. Silvennoinen, O., et al. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc. Natl. Acad. Sci. USA. 90, 8429−8433 (1993). | PubMed  | ChemPort |
  31. Caracciolo, D., et al. Lineage-specific requirement of c-abl function in normal hematopoiesis. Science. 245, 1107−1110 (1989). | PubMed  | ISI | ChemPort |
  32. Martiat, P., et al. Retrovirally transduced antisense sequences stably suppress p210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing Cell lines. Blood. 81, 502−509 (1993). | PubMed  | ISI | ChemPort |
  33. Oda, T., et al. CRKL is the major tyrosine phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J. Biol. Chem. 269, 22925−22928 (1994). | PubMed  | ISI | ChemPort |
  34. Evans, C.A., Owen-Lynch, P.J., Whetton, A.D. & Dive, C. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic Cells. Cancer Res. 53, 1735−1738 (1993). | PubMed  | ISI | ChemPort |
  35. Bedi, A., Zehnbauer, B.A., Barber, J.P., Sharkis, S.J. & Jones, R.J. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 83, 2038−2044 (1994). | PubMed  | ISI | ChemPort |
  36. Heldin, C.H. & Westermark, B. Platelet-derived growth factor: Mechanism of action and possible in vivo function. Cell Regul. 1, 555−566 (1990). | PubMed  | ISI | ChemPort |
  37. Kanakura, Y., et al. Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves a common set of cytoplasmic proteins. Blood. 76, 706−715 (1990). | PubMed  | ISI | ChemPort |
  38. Greenberger, J.S., Sakakeeny, M.A., Humphries, R.K., Eaves, C.J., & Eckner, R.J. Demonstration of permanent factor-dependent multipotential (erythroid/neu-trophil/basophil) hematopoietic progenitor cell lines. Proc. Natl. Acad. Sci. USA. 80, 2391−2395 (1983).
  39. Avanzi, G.C., et al. Selective growth response to IL-3 of a human leukaemic Cell line with megakaryoblastic features. Br. J. Haematol. 69, 359−366 (1988). | PubMed  | ISI | ChemPort |
  40. Matsuguchi, T., et al. SHC phosphorylation in myeloid cells is regulated by GM-CSF, IL-3, and steel factor and is constitutively increased by p210BCR-ABL. J. Biol. Chem. 269, 5016−5021 (1994). | PubMed  | ISI | ChemPort |
  41. Erwin, J.L. & Anderson, S.M. Analysis of phosphotyrosine-containing proteins present in v-src-infected myeloid progenitor cells. Oncogene 7, 1101−1107 (1992). | PubMed  | ISI | ChemPort |
  42. Mossman, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55−63 (1983). | Article | PubMed  |
  43. Orkin, S.H., Harosi, F.I. & Leder, P. Differentiation in erythroleukemia cells and their somatic hybrids. Proc. Natl. Acad. Sci. USA. 72, 98−102 (1975). | PubMed  | ChemPort |
  44. Buchdunger, E., et al. 4,5-Dianilinophthalimide: A protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc. Natl. Acad. Sci. USA. 91, 2334−2338 (1994). | PubMed  | ChemPort |
  45. Buchdunger, E., et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. USA 92, 2558−2562 (1995). | PubMed  | ChemPort |
  46. Arion, D., Meijer, L., Brizuela, L. & Beach, D. cdc2 is a component of the M phase-specific histone HI kinase: Evidence for identity with MPF. Cell. 55, 371−378 (1988). | Article | PubMed  | ISI | ChemPort |
  47. Pendergast, A.M., et al. Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc. Natl. Acad. Sci. USA. 88, 5927−5931 (1991). | PubMed  | ChemPort |
  48. Kharbanda, S., et al. Activation of the c-abl tyrosine kinase in stress response to DNA-damaging agents. Nature. 376, 785−788 (1995). | Article | PubMed  | ISI | ChemPort |
  49. Evans, B.D., Smith, I.E., Shorthouse, A.J. & Millar, J.L. A comparison of the response of human lung carcinoma xenografts to vindesine and vincristine. Br. J. Cancer. 45, 466−468 (1982). | PubMed  | ISI | ChemPort |
  50. Segal, G.M., et al. Repression of Fanconi anemia gene (FACC) expression inhibits growth of hematopoietic progenitor Cells. J. Clin. Invest. 94, 846−852 (1994). | PubMed  | ISI | ChemPort |
  51. Hernandez, A., et al. Detection of the hybrid BCR/ABL messenger RNA in single CFU-GM colonies using the polymerase chain reaction. Exp. Hematol. 18, 1142−1144 (1990). | PubMed  | ISI | ChemPort |
  52. Dunn, O.J. Multiple comparisons using rank sums. Technometrics 6, 241−252 (1964). | ISI |
 Top
 Top
Abstract
Previous | Next
Table of contents
Download PDFDownload PDF
Send to a friendSend to a friend
Save this linkSave this link

naturejobs

natureevents

References
Export citation
Export references
natureproducts

Search buyers guide:

 
ADVERTISEMENT
 
Nature Medicine
ISSN: 1078-8956
EISSN: 1546-170X
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | For authors | Online submission | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | Reprints and permissions | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©1996 Nature Publishing Group | Privacy policy